Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound and oxazine technology, applied in the field of medicine, can solve the problems of poor stability and low content of natural flavonoids, and achieve the effect of a simple synthesis method
Inactive Publication Date: 2013-02-13
SHENYANG PHARMA UNIVERSITY
View PDF4 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0007] However, the content of natural flavonoids is low, and the stability of 4-chromanone Mannich bases is poor. We have modified the structure of flavonoids and 4-chromanones, designed and synthesized a series of oxazines to overcome The aforementioned disadvantages of natural flavonoids and 4-chromanones
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0026] Example 1: 3-Benzyl-2,3,4,6,7,8-hexahydrochromeno[6,7-e][1,3]oxazine
[0027] Dissolve 5 mmol of 7-hydroxychroman in 2 mL of 95% ethanol, add 1.2 mL of 37% formaldehyde aqueous solution, stir for a few minutes, add dropwise 5 mmol of 7-hydroxychroman dissolved in 2-3 mL of 95% ethanol under ice cooling Benzylamine, stirred overnight at room temperature, concentrated and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 30:1) to obtain 3-benzyl-2,3,4,6,7,8-hexahydrochromene [6,7-e][1,3]oxazine as a white solid, yield: 31%. MS m / z (M) 281.35. 1 HNMR (CDCl 3 ):δ2.04(2H,m),2.55(2H,m),3.62(4H,s),3.94(2H,m),5.01(2H,s),6.11(1H,s),6.70(1H, s), 7.10(5H,m).
Embodiment 2
[0028] Example 2: 3-Phenyl-2,3,4,6,7,8-Hexahydrochromeno[6,7-e][1,3]oxazine
[0029] According to the method of Example 1, the white solid 3-phenyl-2,3,4,6,7,8-hexahydrochromeno[6 was obtained by reacting 7-hydroxychroman with aqueous formaldehyde and aniline and separated by column chromatography. ,7-e][1,3]oxazine, yield: 42%. MS m / z (M) 267.32. 1 HNMR (CDCl 3 ): δ2.04(2H,m),2.55(2H,m), 3.94(2H,m), 4.61(2H,s), 6.00(2H,s), 6.11(1H,s), 6.60(3H, m), 6.70(1H,s), 7.08(2H,m).
Embodiment 3
[0030] Example 3: 3-(2-methylphenyl)-2,3,4,6,7,8-hexahydrochromeno[6,7-e][1,3]oxazine
[0031] According to the method of Example 1, the white solid 3-(2-methylphenyl)-2,3,4,6,7 was obtained by reacting 7-hydroxychroman with formaldehyde aqueous solution and 2-methylaniline and separated by column chromatography ,8-Hexahydrochromeno[6,7-e][1,3]oxazine, yield: 37%. MS m / z (M) 281.35. 1 HNMR (CDCl 3 ): δ2.04(2H,m), 2.35(3H,s), 2.55(2H,m),3.94(2H,m),4.61(2H,s),6.00(2H,s),6.11(1H, s), 6.47(2H,m), 6.70(1H,s), 6.88(2H,m).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention belongs to the technical field of medicine, and relates to an oxazine compound and medical application thereof. The oxazine compound and pharmaceutically-applicable salt thereof formed by the addition with acid can be used as a platelet aggregation inhibitor. The structural general formula is shown in the specification. In the structural formula I or II or III or IV or V or VI, R can be independently selected from H, C1-C4 alkyl and benzyl, or substituted or unsubstituted aryl. The synthesis method of the compound provided by the invention is simple and is applicable to industrial production; the compound is more stable in comparison with natural analogs; and biological activity tests show that the compound has analgesic, antiphlogistic and anticoagulant activities. Thus, the compound is a platelet aggregation inhibitor.
Description
[0001] This application is a divisional application filed by Shenyang Pharmaceutical University on February 9, 2009 with the application number 200910010321.9 and the title of the invention "New oxazine compounds and their anti-platelet aggregation application". technical field [0002] The invention belongs to the technical field of medicine, and relates to oxazine compounds and their anti-platelet aggregation application. technical background [0003] Clinical studies have shown that common cardiovascular and cerebrovascular diseases such as hypertension, diabetes, angina pectoris, myocardial infarction, cerebral infarction, and cerebral hemorrhage are all related to changes in platelet function and abnormal blood rheology (Tianjin Medicine, 1992, 20 (11): 684). Therefore, preventing platelet aggregation is of great significance. [0004] Platelets are produced by the lysis of mature megakaryocytes in the bone marrow. The newly formed platelets are large in size, have...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more